X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2019 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare ALEMBIC PHARMA with Wockhardt - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

ALEMBIC PHARMA vs WOCKHARDT - Comparison Results

WOCKHARDT 
   Change

Wockhardt is one of the leading domestic pharmaceutical companies with strong presence in the lifestyle segment and a growing focus on biotechnology. While the company made a string of acquisitions in the past namely 'Esparma GmbH' in Germany, 'Pinew... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    ALEMBIC PHARMA WOCKHARDT ALEMBIC PHARMA/
WOCKHARDT
 
P/E (TTM) x 16.4 -18.6 - View Chart
P/BV x 3.6 1.3 275.0% View Chart
Dividend Yield % 1.1 0.0 35,949.9%  

Financials

 ALEMBIC PHARMA   WOCKHARDT
EQUITY SHARE DATA
    ALEMBIC PHARMA
Mar-19
WOCKHARDT
Mar-18
ALEMBIC PHARMA/
WOCKHARDT
5-Yr Chart
Click to enlarge
High Rs6641,012 65.6%   
Low Rs412532 77.6%   
Sales per share (Unadj.) Rs208.7355.9 58.7%  
Earnings per share (Unadj.) Rs31.0-60.3 -51.4%  
Cash flow per share (Unadj.) Rs37.1-46.8 -79.4%  
Dividends per share (Unadj.) Rs5.500.01 55,000.0%  
Dividend yield (eoy) %1.00 78,867.1%  
Book value per share (Unadj.) Rs144.2257.8 55.9%  
Shares outstanding (eoy) m188.52110.63 170.4%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x2.62.2 118.9%   
Avg P/E ratio x17.4-12.8 -135.6%  
P/CF ratio (eoy) x14.5-16.5 -87.9%  
Price / Book Value ratio x3.73.0 124.7%  
Dividend payout %17.70 -106,951.6%   
Avg Mkt Cap Rs m101,46185,379 118.8%   
No. of employees `000NA6.3 0.0%   
Total wages/salary Rs m7,4679,371 79.7%   
Avg. sales/employee Rs ThNM6,295.0-  
Avg. wages/employee Rs ThNM1,498.3-  
Avg. net profit/employee Rs ThNM-1,066.3-  
INCOME DATA
Net Sales Rs m39,34739,369 99.9%  
Other income Rs m941,202 7.8%   
Total revenues Rs m39,44140,571 97.2%   
Gross profit Rs m8,73618 47,736.6%  
Depreciation Rs m1,1521,495 77.1%   
Interest Rs m1842,555 7.2%   
Profit before tax Rs m7,493-2,830 -264.8%   
Minority Interest Rs m110-   
Prior Period Items Rs m-930-   
Extraordinary Inc (Exp) Rs m0-3,582 0.0%   
Tax Rs m1,568257 609.9%   
Profit after tax Rs m5,844-6,669 -87.6%  
Gross profit margin %22.20 47,763.5%  
Effective tax rate %20.9-9.1 -230.3%   
Net profit margin %14.9-16.9 -87.7%  
BALANCE SHEET DATA
Current assets Rs m19,57733,796 57.9%   
Current liabilities Rs m14,89626,917 55.3%   
Net working cap to sales %11.917.5 68.1%  
Current ratio x1.31.3 104.7%  
Inventory Days Days9079 113.1%  
Debtors Days Days4589 50.8%  
Net fixed assets Rs m27,09739,664 68.3%   
Share capital Rs m377553 68.1%   
"Free" reserves Rs m26,81127,968 95.9%   
Net worth Rs m27,18828,522 95.3%   
Long term debt Rs m4,99321,731 23.0%   
Total assets Rs m47,77881,620 58.5%  
Interest coverage x41.7-0.1 -38,785.6%   
Debt to equity ratio x0.20.8 24.1%  
Sales to assets ratio x0.80.5 170.7%   
Return on assets %12.6-5.0 -250.3%  
Return on equity %21.5-23.4 -91.9%  
Return on capital %23.6-7.7 -307.5%  
Exports to sales %00-   
Imports to sales %00-   
Exports (fob) Rs mNANA-   
Imports (cif) Rs mNANA-   
Fx inflow Rs m19,4539,807 198.4%   
Fx outflow Rs m6,0651,789 339.1%   
Net fx Rs m13,3888,019 167.0%   
CASH FLOW
From Operations Rs m8,120684 1,186.4%  
From Investments Rs m-7,5566,302 -119.9%  
From Financial Activity Rs m590-7,695 -7.7%  
Net Cashflow Rs m1,153-664 -173.7%  

Share Holding

Indian Promoters % 74.1 74.5 99.5%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 2.9 2.3 126.1%  
FIIs % 9.1 7.7 118.2%  
ADR/GDR % 0.0 0.1 -  
Free float % 13.9 15.4 90.3%  
Shareholders   49,328 67,757 72.8%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare ALEMBIC PHARMA With:   ABBOTT INDIA  JUBILANT LIFE SCIENCES  DIVIS LABORATORIES  PIRAMAL ENTERPRISES  NATCO PHARMA  

Compare ALEMBIC PHARMA With:   MYLAN (US)  ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Sensex Ends 560 Points Lower; Auto and Banking Stocks Witness Huge Selling(Closing)

India share markets continued to witness selling pressure during closing hours and ended their day deep in the red.

Related Views on News

ALEMBIC PHARMA 2018-19 Annual Report Analysis (Annual Result Update)

Jun 13, 2019 | Updated on Jun 13, 2019

Here's an analysis of the annual report of ALEMBIC PHARMA for 2018-19. It includes a full income statement, balance sheet and cash flow analysis of ALEMBIC PHARMA. Also includes updates on the valuation of ALEMBIC PHARMA.

ALEMBIC PHARMA Announces Quarterly Results (4QFY19); Net Profit Up 28.9% (Quarterly Result Update)

May 9, 2019 | Updated on May 9, 2019

For the quarter ended March 2019, ALEMBIC PHARMA has posted a net profit of Rs 1 bn (up 28.9% YoY). Sales on the other hand came in at Rs 9 bn (up 8.6% YoY). Read on for a complete analysis of ALEMBIC PHARMA's quarterly results.

WOCKHARDT Announces Quarterly Results (4QFY19); Net Profit Up 90.8% (Quarterly Result Update)

May 7, 2019 | Updated on May 7, 2019

For the quarter ended March 2019, WOCKHARDT has posted a net profit of Rs 139 m (up 90.8% YoY). Sales on the other hand came in at Rs 10 bn (down 3.8% YoY). Read on for a complete analysis of WOCKHARDT's quarterly results.

WOCKHARDT LTD. Announces Quarterly Results (3QFY19); Net Profit Down 80.6% (Quarterly Result Update)

Jan 29, 2019 | Updated on Jan 29, 2019

For the quarter ended December 2018, WOCKHARDT LTD. has posted a net profit of Rs 769 m (down 80.6% YoY). Sales on the other hand came in at Rs 10 bn (up 4.0% YoY). Read on for a complete analysis of WOCKHARDT LTD.'s quarterly results.

ALEMBIC PHARMA 2017-18 Annual Report Analysis (Annual Result Update)

Dec 21, 2018 | Updated on Dec 21, 2018

Here's an analysis of the annual report of ALEMBIC PHARMA for 2017-18. It includes a full income statement, balance sheet and cash flow analysis of ALEMBIC PHARMA. Also includes updates on the valuation of ALEMBIC PHARMA.

More Views on News

Most Popular

These 3 Smallcap Stocks are Set to Make the Most of Smallcap Rebound(Profit Hunter)

Jul 9, 2019

As the sense of normalcy returns to the markets, the rebound in the quality smallcaps could be huge.

2 Stocks from Super Investor Sanjay Bakshi's Portfolio You Can Bet On...(The 5 Minute Wrapup)

Jul 12, 2019

Despite the current fear prevailing in the markets, both these stocks have the potential to deliver in 4-5 years.

After Disappointing Budget, Here's a Document that Concerns Largecap and Smallcap Investors(The 5 Minute Wrapup)

Jul 8, 2019

A new 'definition' of the stock universe that triggered the smallcap sell-off is back with the latest list...

Here's What to Do with Falling Small Cap Stocks(Profit Hunter)

Jul 10, 2019

There are some great buying opportunities in the market right now - and the small cap space is your best bet.

Budget an Icing on the Cake for This Smart Money Backed Affordable Housing Stock(The 5 Minute Wrapup)

Jul 10, 2019

Affordable housing is one of the most straightforward growth stories in India. This will help the real estate sector to come out of the slump.

More

Get the Indian Stock Market's
Most Profitable Ideas

How To Beat Sensex Guide 2019
Get our special report, How to Beat Sensex Nearly 3X Now!
We will never sell or rent your email id.
Please read our Terms

ALEMBIC PHARMA SHARE PRICE


Jul 19, 2019 03:35 PM

TRACK ALEMBIC PHARMA

  • Track your investment in ALEMBIC PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON ALEMBIC PHARMA

ALEMBIC PHARMA 8-QTR ANALYSIS

COMPARE ALEMBIC PHARMA WITH

MARKET STATS